We previously developed a multivariate model based on the RNA expression of six genes -LMO2, BCL6, FN1, CCND2, predicts survival in DLBCL patients. Since LMO2 emerged as the strongest predictor of superior outcome, we generated a monoclonal anti-LMO2 antibody in order to study its tissue expression pattern. Immunohistological analysis of over 1200 normal and neoplastic tissue and celllines showed that LMO2 protein is expressed as a nuclear marker in normal germinal center (GC) B-cells, GC-derived B-cell lines and in a subset of GC-derived B-cell lymphomas. LMO2 was also expressed in erythroid and myeloid precursors and in megakaryocytes, and also in lymphoblastic and acute myeloid leukemias. It was rarely expressed in mature T, NK and plasma cell neoplasms and was absent from nonhematolymphoid tissues except for endothelial cells. Hierarchical cluster analysis of immunohistologic data in DLBCL demonstrated that the expression profile of the LMO2 protein was similar to that of other GC-associated proteins (HGAL, BCL6 and CD10) but different from that of non-GC proteins (MUM1/IRF4 and BCL2). Our results warrant inclusion of LMO2 in multivariate analyses to construct a clinically applicable immunohistologic algorithm for predicting survival in patients with DLBCL.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL), the most common adult non-Hodgkin lymphoma, is well recognized as a heterogeneous entity in which less than half of all affected patients are cured by currently available therapies. 1, 2 Although clinical indicators such as the International Prognostic Index (IPI) are used to define prognostic subgroups of DLBCL, 3 these surrogates fail to fully reflect the underlying heterogeneity of the disease since patients with identical IPI can have strikingly different outcomes. A pivotal study in 2000, employing gene expression profiling, reported that DLBCL could be classified into two molecularly distinct subtypes: germinal center B cell (GCB)-like DLBCL exhibiting a gene expression signature similar to normal germinal center B-cells;
and activated B-cell (ABC)-like DLBCL, typified by the gene expression signature of stimulated peripheral blood B-cells. 4 The overall survival in patients treated with anthracycline-containing chemotherapy was significantly longer for GCB-like DLBCL compared to ABC-like DLBCL. 4 That study led to the construction of several models predicting survival of DLBCL patients based on RNA and protein expression; 5 however, a consensus approach for predicting DLBCL prognosis and risk-adapted management of this lymphoma has not been achieved.
To this end, we previously evaluated 36 genes that were reported to predict survival in DLBCL, correlating their expression levels (as measured by quantitative RT-PCR) with their ability to predict survival in univariate analyses. 6 The six genes with the strongest predictive value, LMO2, BCL6, FN1, CCND2, SCYA3 and BCL2, were then selected to construct a multivariate model that predicted survival in a second independent cohort of DLBCL patients. 6 For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From
The gene with the strongest predictive power for long survival, LMO2 (also known as RBTN2 and TTG2), is a cystein-rich LIM domain-containing transcription factor that plays an important role in angiogenesis and erythropoiesis and is required for definitive hematopoiesis during mouse embryogenesis. 7, 8 In humans, it is activated by chromosomal translocations at t(11;14)(p13;q11) or t(7;11)(q35;p13) in T-cell acute lymphoblastic lymphoma/leukemia (T-ALL). 9 LMO2 is not expressed in mature T-cells 10 but its mRNA is widely detected in fetal tissues, particularly, in the liver. 11 Its expression has also been reported in adult spleen and human B-cell lines, 11 and, more recently, in germinal center B-cells. 4 However, despite these extensive studies of LMO2 mRNA expression and it role in mouse hematopoiesis, thymic development and leukemogenesis, the distribution of the protein in tissue has not been studied. We have therefore generated a monoclonal anti-LMO2 antibody and characterized LMO2 protein expression in normal and neoplastic hematopoietic and non-hematopoietic tissues. A comparison of the LMO2 protein expression profile with that of other well-characterized GC markers such as HGAL, BCL6, and CD10, and non-GC markers such as BCL2 and MUM1/IRF4, was undertaken to determine whether LMO2 expression correlates with prognostic subclasses of DLBCL.
MATERIALS AND METHODS

Generation of Monoclonal Anti-LMO2 Antibody
We generated a GST-LMO2 construct in pGEX-2T vector (Pharmacia Biotech, Uppsala, Sweden for the first and two subsequent injections, respectively. Injections were given into the footpads of mice at 2-week intervals, followed by 3 injections every 3 days prior to undertaking fusion of draining lymph node or spleen cells to K6H6B5 fusion partner hybridoma cells, as reported previously. 12 ELISA using GST-LMO2 fusion protein or an unrelated GST fusion protein was used for initial screening of hybridoma supernatants.
The secreting hybridoma cells were subcloned by serial dilution and then further screened for specific antibody production by immunobloting cellular lysates from LMO2 (6) , parathyroid (4), prostate (3), stomach (2), thyroid (2) and uterus (4) as well as glioblastoma multiforme (2), seminoma (2) and soft tissue sarcomas (13) .
Cell lines:
The cell lines used in this study include two cell lines classified as GCB-like (SU- 
Immunoblot Analysis
Whole cell extracts for immunoblot analysis were prepared by lysing cells (5x10 6 ) with RIPA buffer (1X phosphate-buffered saline (PBS), 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and 10mM phenylmethylsulfonyl fluoride, 1µg/ml Aprotinin, For personal use only. on October 28, 2017. by guest www.bloodjournal.org From been described previously. 13 Double immunofluorescence labeling was performed as previously described. 15 Antibodies to CD20, CD3, myeloperoxidase (MPO), glychophorin A and CD79a were purchased from DAKO Corporation. Anti-LAT antibody was kindly provided by Professor V. Horejsi, University of Prague, Czech Republic.
Data analysis and visualization
The stained lymphoma TMA slides were scanned and stored as high resolution images using an automated scanner (Bacus Laboratories, Inc., Slide Scanner (BLISS) http://www.bacuslabs.com). The "Deconvoluter" algorithm (custom WBS macro, Excel, Microsoft) with appropriate layout for use in the Cluster software was used for hierarchical clustering to integrate all immunohistologic staining results as previously described (http://genome-www.stanford.edu/TMA/). 16 Positive staining is represented as red, lack of staining as green and non-interpretable staining as white.
RESULTS
Specificity of anti-LMO2 antibody
The specificity of the anti-LMO2 monoclonal antibody 1A9-1 was In normal thymus LMO2 protein and staining was restricted to rare scattered lymphocytes, the majority of which were found in the medulla. In the spleen, germinal centers within secondary lymphoid follicles of the white pulp showed LMO2 staining whereas the mantle and marginal zones lacked staining. As shown in Figure 2 Similarly, megakaryocytes, detected by immunofluoresence staining for LAT, showed moderate to strong staining for LMO2.
Expression of LMO2 Protein in Hematolymphoid Neoplasia
Results of immunohistologic staining in hematolymphoid neoplasia are summarized in Table 1 , and specific examples are illustrated in Figure 3 . 
was further studied in 143 cases of DLBCL compared to that of five additional markers, HGAL, BCL6, CD10, BCL2 and MUM1/IRF4, documented in our previous work. 13 Hierarchical cluster analysis demonstrated that LMO2 protein correlated with the expression patterns of GC-specific markers HGAL, BCL6 and CD10, but not with non-GC markers MUM1/IRF4 or BCL2 (Figure 4) However, despite these extensive investigations based on the assessment of mRNA levels, there have been no studies of LMO2 at the protein level. In this paper we document for the first time, using a newly generated antibody reactive with routinely processed biopsy tissue, the expression of LMO2 in normal and neoplastic human tissues. Our results not only throw new light on the site of expression of LMO2 but also document a unique antibody that is suitable for use in the routine hematopathology laboratory.
In normal bone marrow we found that all three hematopoietic lineages expressed LMO2 protein, although in the myeloid and erythroid series this expression appeared to disappear with differentiation. These results are in keeping with prior mRNA studies 25 and they underscore the central role of LMO2 in hematopoiesis. Its physiologic expression in bone marrow may also be relevant to our observation of LMO2 expression in 8/10 cases of AML (which is in keeping with published mRNA studies 25 ) and in neoplastic megakaryocytes in CML.
We also observed LMO2 expression in non-myeloid acute leukemia, namely in 8/14 cases of T-ALL and 5/12 cases of B-ALL. It is well recognized that LMO2 mRNA is overexpressed in many more cases of T-ALL than carry the t(11;14)(p13;q11) and t(7;11)(q35;p13) translocations, and this is comparable to the aberrant overexpression of other transcription factors, e.g. HOX11, TAL1, in T-ALL in the absence of cytogenetic abnormalities. 25 It is not clear whether this expression in the absence of translocation reflects derivation of the leukemias from a T-cell precursor that normally expresses LMO2, or whether there is a leukemia-specific mechanism of LMO2 activation. In the former context, LMO2 protein in the thymus in the present study was confined to a few scattered cells in the medulla and cortex. This finding corroborates studies in mouse embryogenesis where LMO2 mRNA is absent from fetal and adult thymus (but present in many other fetal tissue). 11 However, Asnafi and colleagues have shown that LMO2 is most commonly expressed in T-ALLs derived from immature, CD4-and CD8-negative (double negative, DN1-2 stage) thymocytes. These are present in normal thymus as a very minor population, residing near the cortico-medullary junction, and they may not be detectable by conventional immunostaining of the thymus due to their rarity. However, it is also possible that the normal equivalent of T-ALL lacks LMO2 and that a specific genetic alteration mechanism causes LMO2 deregulation leading to oncogenesis. Some support for this hypothesis comes from recent studies that have shown frequent biallelic activation of one or more transcription factors in T-ALL, indicating that aberrant cisacting regulatory elements are not the only pathway to induction of leukemias. 26 The observed expression of LMO2 protein in 5/12 cases of B-ALL may also reflect their derivation from a B-cell precursor that normally expresses this transcription factor, and more studies to address this possibility are in progress. In this context, it may be relevant that Foroni and colleagues previously predicted a role for LMO2 in B-cell development based on the expression of LMO2 mRNA in mouse fetal liver, adult spleen and B-cell lines.
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Our observation that LMO2 is expressed in germinal centers is fully in keeping with gene expression profiling studies which showed high levels of LMO2 mRNA in GC Bcells. 4 Our double immunofluorescence results for CD20, CD10 and CD3 confirm that Gene expression profiling has been used successfully to predict prognostic subgroups of DLBCL, but the expense and need for fresh tissue for this technology pose major constraints on its use in routine clinical practice. Several studies have therefore focused on the search for immunohistological markers that can identify risk groups.
However, at present the panel as proposed by Hans et al is based on only three markers, BCL6, CD10 and MUM1, and studies of prognosis based on this and other similar algorithms have yielded conflicting results. 17, [27] [28] [29] [30] [31] We have previously explored the use of two other GC-associated gene products (HGAL and JAW1) whose overexpression at the mRNA has been documented at high levels in GC and GC-derived tumors, and have shown them to be preferentially expressed in GC DLBCL at the protein level. 13, 32 A subset (34%) of our DLBCL cases showed a LMO2 staining pattern that was not consistent with the result that would be expected based on the Hans algorithm. This
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From could be attributed to "promiscuity" of GC markers that result in their expression in a subset of non-GC-derived DLBCL. In the germinal center microenvironment where there is a continuum of B-cell differentiation it is likely that specific GC markers are up-or down-regulated at any one particular stage. However, the expression of any one of the GC markers is independent of its ability, when combined with other markers, to define DLBCL subtypes. Our data raise the important consideration that the "GC profile" likely comprises more than one molecular signature of partially overlapping protein expression patterns that underlie the genetic heterogeneity of DLBCL. Alternatively, LMO2 staining in non-GC derived DLBCL may suggest that the Hans algorithm misclassifies a significant proportion of DLBCL cases. Indeed, in their original paper, approximately 20% of cases were misclassified in comparison to the gold-standard of gene-arraybased classification of the same cases. 17 It is possible that the incorporation of additional newly characterized GC-markers such as LMO2, HGAL and JAW1 may be necessary to improve the robustness of an immunohistologic predictor in the prognostic stratification of patients with DLBCL.
In addition to its interest in the context of DLBCL, immunohistologic detection of LMO2 may be of practical value for the diagnosis of small cell B cell neoplasms, particularly for distinguishing low-grade B-cell lymphomas (marginal zone, lymphoplasmacytic and small lymphocytic neoplasms) from follicular lymphomas. In this regard, LMO2 is similar to HGAL, another GC-specific marker we previously characterized, whose expression is also restricted to GC B-cells. 13 Both markers are therefore superior to BCL6 in distinguishing follicular colonization by marginal zone lymphoma or a diffuse infiltrate of small lymphocytic lymphoma from a true follicular lymphoma. In contrast to HGAL, LMO2 is less frequently expressed in follicular lymphomas. Thus, although both LMO2 and HGAL are highly specific to GC B-cells, the For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From expression of LMO2 is more restricted than HGAL, and in the diagnostic setting, HGAL is a more sensitive marker in the discrimination of a GC-derived lymphoma from its morphologic mimics than is LMO2. On the other hand, the crisp nuclear staining associated with LMO2 protein offers easier interpretation in comparison to the diffuse cytoplasmic staining associated with HGAL. Thus, LMO2 could be extremely valuable in the diagnosis of small tissue samples and needle biopsies.
In conclusion, we have raised an anti-LMO2 antibody and shown that the LMO2 protein is expressed in normal human germinal centers and GC-derived lymphomas. In addition, it is also expressed at high levels in endothelial cells, spleen, hematopoietic precursors and a significant proportion of acute lymphoblastic and myeloid leukemias. In DLBCL, LMO2 protein expression is aligned with GC markers, HGAL, CD10 and BCL6, indicating a potential role for LMO2 in the prognostic stratification of DLBCL patients.
The anti-LMO2 antibody exhibits robust nuclear labeling in paraffin sections and is suitable for hematopathologic diagnosis as well as for the study of leukemogenesis, angiogenesis and thymic development. 
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